Objective: To examine the effect of adding nevirapine (NVP) and/or hydroxyurea (HU) to a triple nucleoside analogue reverse transcriptase inhibitor (NRTI) regimen in terms of efficacy and tolerability.
Introduction
Highly active antiretroviral therapy (HAART), consisting of a combination of two nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor, has been shown to reduce the occurrence of opportunistic infections and death significantly, translating into clinical benefit for those patients who have access to therapy [1] . In addition, protease inhibitorcontaining HAART has been shown to suppress viral replication in a two-thirds of treated patients for up to 3 years [2] . A combination of two NRTI and the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz has been shown to provide better and more durable suppression of viral replication than a protease inhibitor plus two NRTI in treatment-naive chronically HIV-infected patients through 144 weeks of follow-up [3] . Also, in the Atlantic study [4] , the combination of nevirapine (NVP) and two NRTI as first-line therapy for chronic HIV-1 infection displayed similar potent antiviral activity compared with a protease inhibitor-containing or triple NRTI-containing regimen for up to 48 weeks. Guidelines for the initial treatment of chronically HIV-1-infected patients as such have been updated to include the combination of two NRTI plus one NNRTI [5, 6] .
Recently, the use of the triple NRTI regimen, zidovudine (ZDV) plus lamivudine (3TC) plus abacavir (ABC), in antiretroviral treatment-naive patients has been shown to be at least as effective as the protease inhibitor-containing triple drug regimen ZDV/3TC/ indinavir in terms of achieving plasma HIV-1 RNA , 400 copies/ml at 48 weeks [7] . However, when an assay with a lower limit of quantification (LLQ) of 50 copies/ml was used, the protease inhibitor-containing regimen proved superior in terms of suppression of viral replication below this limit in patients with a pretreatment plasma HIV RNA level . 100 000 copies/ ml.
Although the current stated goal of antiretroviral therapy is complete inhibition of viral replication [6] , it is becoming increasingly clear this goal cannot be met by standard triple drug regimens. Ongoing residual viral replication was shown to occur, albeit at low levels, in peripheral blood of a group of highly selected patients who had a long-term response to therapy (plasma HIV-1 RNA , 50 copies/ml, conventional assay), when an experimental ultrasensitive assay with a LLQ of 5 copies/ml [8] or 3 copies/ml [9] was used. Also, on a cellular level, evidence exists of incomplete suppression of viral replication during successful triple drug therapy, such as the continued expression of viral RNA in lymphoid tissue [10] , sequence evolution in the viral envelope gene [11] , unintegrated circular forms of HIV-1 DNA associated with peripheral blood mononuclear cells [12] , and the selection of drug resistance-associated mutations [13] .
It was previously shown that implementation of the five-drug triple class regimen ZDV/3TC/ABC/NVP/ indinavir led to an accelerated initial decline (over 12 weeks) in plasma HIV RNA level in nine treatmentnaive subjects compared with that achieved with a standard triple drug regimen [14] . After 144 weeks of therapy with the same multidrug regimen, improved suppression of viral replication compared with standard therapy was still observed [15] .
Around 1998, the use of hydroxyurea (HU) gained popularity, after preliminary studies had shown that the addition of HU to didanosine (ddI) monotherapy resulted in a significant and prolonged suppression of viral replication, both in naive and in ZDV-pretreated patients [16] [17] [18] . Randomized, controlled studies followed. In one study [19] , the addition of HU to ddI resulted in a significantly higher decrease in plasma HIV-1 RNA compared with ddI monotherapy at 24 weeks, while in another [20] , HU was shown to improve the antiviral activity of the dual NRTI combination ddI plus stavudine (d4T) over a 12 week period.
The use of HU has also been studied in the context of triple combination drug therapy [21, 22] . In the 3D study [21] , 147 patients were randomized 2 : 1 to add HU (600 mg twice daily) or placebo to efavirenz plus ddI plus d4T. At 48 weeks, there was no difference in efficacy among treatment-naive patients. In addition, 31 patients who added HU experienced significant adverse events compared with 19 in the placebo group. In the ACTG 5025 study [22] , subjects who had been successfully treated with ZDV/3TC/indinavir for at least 6 months were randomized to continue this treatment or to switch to d4T/ddI/indinavir with or without HU 600 mg twice daily. No virological or immunological differences were found, but there was a higher incidence of toxicities with HU, including two deaths caused by pancreatitis. In both studies [21, 22] , the use of HU was discontinued prematurely by the Drug Safety and Monitoring Board because of increased toxicity. When the CHARM study was designed, data on the efficacy and toxicity of HU when used as a component of triple antiretroviral combination drug therapy was scarce.
been described include alopecia, gastrointestinal disorders (nausea and vomiting) and transient elevation of liver enzymes [24] .
The observation that HU enhances the in vitro anti-HIV activity of a thymidine analogue (d4T) and cytidine analogue (3TC) NRTI by increasing their intracellular phosphorylation [25, 26] provides a rationale for combining HU with these drugs. However, there is no in vivo proof that this is the mechanism. The clinical benefit of adjunctive HU therapy in combination with other nucleosides remains an important research question. In addition, given the unique features of HU, such as ease of administration, limited drug interactions and low cost, its possible role in simplified treatment regimens that target populations in developing countries is particularly appealing.
The aim of the study was to investigate the effect of adding NVP and/or HU to the triple NRTI regimen ZDV/3TC/ABC in terms of efficacy and tolerability. In addition, the study examined the effect of adjuvant prednisolone during the first 2 weeks of therapy on the development of hypersensitivity reactions associated with ABC and NVP. Results of this additional analysis have been published elsewhere [27] .
Methods

Study participants
The main eligibility criteria for inclusion in this study were documented HIV-1 infection by a licensed HIV-1 antibody enzyme-linked immunosorbent assay (ELISA), no previous exposure to antiretroviral drug therapy (prior NRTI exposure for less than 2 weeks was permitted), plasma HIV-1 RNA at least 5000 copies/ml within 4-12 weeks of study drug administration and a negative serum pregnancy test (human beta-chorionic gonadotrophin) at screening for women of child-bearing potential. There was no entry criterion for CD4 cell count. Patients were excluded they were known to have experienced clinically relevant pancreatitis or neuropathy during the 6 month period preceding screening; if they had hepatic dysfunction evident by grade III or IV hyperbilirubinaemia (ACTG toxicity grading scale) or aspartate transaminase . 5 times the upper limit of normal (local laboratory limits); if they had renal failure requiring dialysis; or if any of the following laboratory parameters were present during the 4 week period prior to study drug administration: a haemoglobin concentration , 10.0 g/dl (6.3 mmol/l) for men and , 9.0 g/dl (5.7 mmol/l) for women, neutrophil count , 1 3 10 9 cells/l, thrombocyte count , 75 3 10 9 cells/l and a serum pancreatic amylase . 1.5 times the upper limit of normal. Subjects were also excluded if they were pregnant or breastfeeding; had received radiation therapy or cytotoxic chemotherapeutic agents within 30 days of study drug administration (or had an anticipated need for such treatment), with the exception of localized treatment for Kaposi's sarcoma; had received treatment with immunomodulating agents such as systemic corticosteroids, interleukins or interferons within 30 days of study drug administration; abused alcohol; or had a severe HIVrelated or non-HIV-related disease incompatible with study treatment, as judged by the investigator.
Study design
This 72-week open-label, randomized, multicentre study was conducted at 21 sites in South Africa, Canada, western and eastern Europe. The institutional review boards and independent ethics committee at each site approved the study and all patients gave written informed consent before initiating the study. The study had a factorial design. All patients who entered the study received ZDV, 3TC and ABC. When possible, ZDV and 3TC were given as the combination tablet Combivir 1 . In this factorial design, subjects were first allocated to the addition or not of NVP. Second, subjects were randomized to the addition or not of HU. Finally, there was a third randomization to the addition or not of prednisolone during the first 2 weeks of the study, with the intention to prevent hypersensitivity reactions associated with NVP and ABC. Study dosages were ZDV 300 mg twice daily, 3TC 150 mg twice daily, ABC 300 mg twice daily, HU 500 mg twice daily, NVP 200 mg once daily during the first 14 days of treatment, followed by 200 mg twice daily from day 15 onwards, and prednisolone 40 mg once daily during the first 14 days only. Subjects were to continue their randomized treatment until 72 weeks follow-up unless they met protocoldefined criteria for premature treatment discontinuation, such as treatment failure, pregnancy, withdrawal of written consent or experienced treatment-related adverse events sufficiently severe to discontinue randomized treatment prematurely.
Study monitoring
Study visits were scheduled for week À4 (screening visit), week À2, week 0 (baseline visit and start of study medication), and weeks 2 (dose escalation of NVP and discontinuation of prednisolone), 4, 6, 12, 24, 36, 48, 60 and 72. At week À4, subjects signed informed consent and were screened to see whether they met all entry criteria. If not previously recorded, seropositive status for HIV-1 infection was confirmed by a licensed HIV-1 antibody ELISA test. A serum pregnancy test was performed where applicable and was repeated at weeks 12, 24, 36 and 48. Current medical conditions, HIV-associated conditions, classification according to the Center for Disease Control (CDC), weight, the use of concurrent medications and/or blood products were recorded, and haematology, clinical chemistry, lympho-cyte subsets (using flow cytometry), quantitative HIV-1 RNA measurement [Roche Amplicor version 1.5 (Roche Molecular Systems, Branchburg, New Jersey, USA) with a LLQ of 50 copies/ml] were measured at each study visit. A plasma sample was also collected. All laboratory assays were performed at the local laboratory with the exception of HIV-1 RNA and sample storage, which were carried out at a central laboratory. At week À2, demography, risk factors or mode of transmission and height were recorded and serology for hepatitis B and C was done. Safety assessments were based on evaluations of medical history, vital signs, haematology, clinical chemistry, urinalysis and clinical adverse experiences. The last were evaluated using the ACTG toxicity grading tables for grading severity of adult adverse experiences. Clinical Research Associates monitored the different study sites for consistency of data and laboratory tests performed at the local laboratories. An independent Data and Safety Monitoring Board reviewed safety and efficacy data once all subjects completed 24 weeks follow-up.
Outcome measurements
A factorial study design was chosen to allow for independent consideration of the effect of adding HU and NVP on treatment outcome. To test whether this assumption was valid, an interaction factor (NVP 3 HU) was calculated to examine the appropriateness of pooling data for analyses. Comparisons in both the efficacy and safety analyses were based on study groups, categorized as follows: NVP use/non-use and HU use/non-use, as opposed to the different treatment arms in the study.
The primary efficacy analysis was a comparison of the different study groups with respect to the proportion of subjects with treatment failure at week 72. The population considered for the primary analysis was the intention-to-treat population and included all randomized subjects, categorizing those subjects who withdrew from the study for any reason as treatment failures. Treatment failure was defined as having a plasma HIV RNA level > 50 copies/ml after week 24 or discontinuation of randomized treatment. Missing plasma HIV-1 RNA measurements were considered to be . 50 copies/ml, unless the measurement preceding and following the missing measurement were both , 50 copies/ml.
In the secondary efficacy analysis, a comparison was made between the different study groups with respect to the proportion of subjects with treatment failure in the as-treated population, consisting only of those subjects still on randomized treatment at week 72. Additionally, the log 10 copies/ml reduction in plasma HIV RNA from baseline was calculated by using an uncensored method, where plasma HIV RNA levels < 50 copies/ml (LLQ of the assay) were set at 50 copies/ml. Also included in the secondary efficacy analyses were the time to reach a plasma HIV RNA level < 50 copies/ml and the time to first virological failure, both in the intention-to-treat population. For the latter analysis, only subjects who had reached a plasma HIV RNA level < 50 copies/ml on or before week 24 were included. Logistic regression analysis was performed in the intention-to-treat population to determine the influence of NVP use, HU use, gender, age, baseline CD4 cell count and baseline plasma HIV RNA level on treatment outcome at week 72.
The change in CD4 cell count from baseline was calculated by study group in the intention-to-treat population. For the purpose of the drug safety analysis, all serious adverse events and additional grade III (severe) and grade IV (life-threatening) adverse events considered to be possibly, probably or almost certainly attributable to the use of the study medication were tabulated by study group. In addition, all grades of treatment-emergent laboratory toxicity, as measured by the ACTG toxicity scale, were summarized by study group. When an event occurred more than once in the same subject, only the highest toxicity grade measured was included in the analysis. A summary was made, by study group, of all adverse events that led to a discontinuation or change in randomized treatment.
Statistical analysis
All analyses were carried out according to a predefined data analysis plan using SAS statistical package version 8.2 (SAS Institute, Cary, North Carolina, USA). The study had 80% power to detect a difference in the proportions of subjects with treatment failure of 0.15 to 0.20 with a significance level of 0.05 between the treatment groups. Differences in proportions were analysed by the chi-squared test. In the logistic regression analysis, variables that were statistically significant in the univariate analysis were used in the multivariate analysis. To test the factorial design assumption of independence of the treatment groups, the interaction between NVP and HU use was tested in a multivariate model, which included NVP use, HU use and their interaction. For analysis of the time to reach plasma HIV RNA , 50 copies/ml and to first virological failure, Kaplan-Meier estimates were produced and tested by a log rank test. The change in CD4 cell count from baseline was analysed by using a 'proc mixed' procedure, which accommodates repeated measurements and estimates mean values by a least square analysis. Treatment group and time were used as covariates in an unstructured matrix.
Results
Baseline characteristics
A total of 229 subjects were enrolled in the study between August 1999 and June 2000. Baseline char-acteristics are shown in Table 1 and study design in Fig. 1 . The two different study groups were balanced with respect to demographic and baseline characteristics.
Subject disposition at week 72
Seven subjects never received randomized, assigned treatment. Thirty-eight subjects prematurely discontinued the study after having received assigned treatment ( Fig. 1 ). Reasons included patient request (n ¼ 18), lost to follow-up (n ¼ 18) and other reasons (n ¼ 2). A total of eight deaths occurred during the study. Four of these deaths were AIDS related (one each of cryptococcal meningitis, tuberculous meningitis, extensive Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Kaposi sarcoma and wasting syndrome). The other deaths were unrelated to HIV disease: one subject died of metastatic carcinoma (aetiology unknown), one committed suicide, one died of mesentery infarction and one of aplastic anaemia. It is possible that the aplastic anaemia was related to ZDV and HU use. After 72 weeks, 177 patients were still in the study, of whom 78 (44%) were still on randomized treatment (Fig. 1) .
Efficacy analysis
No significant interaction was found between NVP use and HU use on treatment outcome, odds ratio 1.36 [95% confidence interval (CI), 0.37-4.99], validating the assumption of independence of effects and allowing for pooling of data ( Table 2) .
Primary efficacy endpoint
The population considered was the intention-to-treat population (n ¼ 229 (Table 3) .
Secondary efficacy endpoints
In the as-treated population (n ¼ 78), in the NVP group, 21.6% (95% CI, 9.8-38.2) of subjects adding NVP versus 48.8% (95% CI, 32.9-64.9) of subjects not adding NVP experienced treatment failure (P ¼ 0.013), while in the HU group there was no significant difference in treatment failure rate between subjects (P ¼ 0.841).
Overall, subjects experienced a median reduction of 2.78 log 10 copies/ml HIV-1 RNA from baseline at week 72, while no significant differences were seen between subjects in the different treatment groups. In the NVP group, the proportion of subjects reaching plasma HIV-1 RNA , 50 copies/ml increased more rapidly over time in NVP users than in non-users (log rank test; P ¼ 0.011; Fig. 2 , while in the HU group no significant difference was observed between subjects.
Kaplan-Meier estimates showed no significant differences between the groups with respect to the time to first virological failure (NVP use versus non-use: logrank P ¼ 0.238; HU use versus non-use: log-rank P ¼ 0.493). In the univariate logistic regression analysis, none of the parameters tested significantly increased the odds ratio of experiencing treatment failure (Table 2) . However, a trend was observed for HU use: odds ratio 1.85 (95% CI, 0.97-3.51).
The change from baseline in absolute CD4 cell count in time by study group is shown in Fig. 3 . There were no treatment effects observed in the NVP group. In the HU group, subjects taking no HU experienced a significantly higher increase in absolute CD4 cell count than did non-users (P , 0.001). However, no significant differences in CD4 cell percentage increase over time was seen between subjects in either treatment
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. group. Disease progression, defined as deterioration in CDC class or death, occurred in 14% of subjects (intention-to-treat). No differences were observed between the different treatment groups.
Safety analysis
One or more serious adverse event, or additional grade III and IV adverse event that was considered treatment emergent, was observed in 59 subjects (51.3%) taking NVP versus 37 subjects (32.5%) not taking NVP in the NVP arm (P ¼ 0.003), and 54 subjects (47.4%) taking HU versus 42 subjects (36.5%) not taking HU in the HU arm (P ¼ 0.096) ( Table 4 ). In the NVP arm, the following events were reported more frequently in NVP users than in non-users: rash (5.2% versus 1.8%), liver toxicities (11.3% versus 1.8%), hypersensitivity reaction to ABC and/or NVP (16.5% versus 5.3%) and gastrointestinal events (13.9% versus 7.9%). In the HU arm, gastrointestinal events (14.9% versus 7.0%), anaemia (16.7% versus 2.6%), neutropenia (17.5% versus 9.6%) and pancytopenia (1.8% versus 0%) were reported more frequently in users than in non-users. One or more adverse events that led to discontinuation of randomized treatment occurred in 60 subjects (52.6%) adding HU versus 33 subjects (28.7%) not adding HU in the HU arm (P , 0.001), and in 55 subjects (47.8%) adding NVP versus 38 subjects (33.3%) not adding NVP in the NVP arm (P ¼ 0.026). In September 2001, the Drug Safety and Monitoring Board unanimously recommended that HU be discontinued because of the unacceptably high proportion of subjects experiencing adverse events that led to a change or discontinuation of randomized treatment. The proportion of subjects with laboratory abnormalities (all grades) was similar between the different treatment groups (data not shown), with the exception of gamma-glutamyl transaminase toxicity, which occurred significantly more frequent in NVP users (P ¼ 0.04).
Discussion
This randomized trial is the first that has allowed independent consideration of the effect of adding NVP and/or HU to a triple NRTI drug regimen in terms of antiviral efficacy and tolerability; this was achieved by the factorial design.
In the NVP group, subjects who added NVP experienced an accelerated decay in plasma HIV-1 RNA. In Fig. 3 , it can be seen that the proportion of subjects reaching 'undetectability' of HIV-1 RNA over time increased more rapidly in NVP users, suggesting that the addition of NVP increased the potency of the triple NRTI regimen. The as-treated analysis, which is a reflection of virological efficacy, confirms this observation. The addition of NVP failed to improve treatment outcome in the intention-to-treat population. This was because a significant proportion of subjects who added NVP experienced one or more adverse events that necessitated a change in randomized treatment. By
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. definition, these subjects were considered treatment failures.
Hypersensitivity reactions to ABC and/or NVP were reported more frequently in subjects allocated to the use of NVP (n ¼ 19; non-users reported 7). As clinical symptoms of NVP-and ABC-associated hypersensitivity reactions overlap, a clear distinction between the two cannot reliably be made. Furthermore, none of the study arms consisted of the use of NVP without ABC, making adequate comparisons between NVP-and ABC-associated hypersensitivity reactions impossible. Therefore, these events were treated as a composite endpoint. In addition, the outcome of ABC hypersensitivity reactions can be fatal if the reaction is not recognized and treatment with ABC discontinued. It is possible that the open-label design of the study may have introduced a bias in reporting the occurrence of hypersensitivity reactions.
More subjects allocated to the use of HU experienced treatment failure at week 72 (intention-to-treat population), although the difference between subjects did not reach significance. The observed difference between subjects resulted from the more frequent occurrence of adverse events in subjects using HU. In the as-treated population, treatment failure was the same in those that did and did not use HU, suggesting that HU use did not improve the antiviral efficacy of the triple NRTI regimen.
The main toxicity encountered in clinical practice with HU is bone marrow suppression, which can lead to neutropenia, anaemia and/or thrombocytopenia [24] . In the HU group, anaemia and neutropenia of severe or life-threatening intensity were reported in 20 and 21 subjects who were allocated to HU versus 3 and 12 subjects not taking the drug, respectively. The myelosuppressive effect of HU has been shown to be enhanced if HU is used in association with other haematotoxic drugs such as ZDV or cotrimoxazole [17] . We are able to confirm this observation.
In our study, 85 (74.6%) of the 114 subjects originally allocated to the use of HU discontinued the drug by week 72. These numbers are comparable with those reported in the long-term follow-up of subjects in the ddH study [28] , where 75% of the 72 patients originally randomized to HU in combination with d4T/ddI and 80% of the 30 patients who elected to add HU after week 12 discontinued the drug 24 months after the start of the trial. In the as-treated population, we have observed a treatment failure rate in the order of 35% in subjects taking HU. Once again, these results are very similar to those reported in the ddH study [28] , where 9/18 (50%) of subjects still taking ddI/d4T/HU and 5/ 15 (33%) taking ddI/d4T had plasma HIV-1 RNA levels . 200 copies/ml after 72 weeks of follow-up.
HU enhances the antiviral activity of adenosine analogues, mainly that of ddI, by decreasing the intracellular dATP pool, which is the natural competitor of ddI at the DNA elongation process [17, 25] . The benefits obtainable with the association of HU with other Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. NRTI are smaller as the reduction of paired dNTP levels is less effective than for dATP competitive inhibitors [29, 30] . This is one possible explanation why addition of HU to the triple NRTI regimen ZDV/ 3TC/ABC did not improve the antiviral efficacy of the regimen.
In a systematic overview of results from clinical trials involving triple drug therapy [31] , the overall estimated percentages of patients with plasma HIV-1 RNA , 50 copies/ml at 48 weeks by drug class were 46% for a regimen containing a protease inhibitor, 51% for one containing a NNRTI, and 45% for triple NRTI. The overall failure rates in our study were much higher, especially for a treatment-naive population.
The primary endpoint of the study was a composite of failure of virological suppression and discontinuation of randomized treatment for any reason. This explains the high failure rate in the intention-to-treat population. In addition, approximately 35% of subjects in the NVP and HU groups failed in the as-treated population. It is possible that this was caused by adherence problems.
Although adherence was measured in the study, insufficient data were collected for analysis.
From an immunological viewpoint, a significant increase in the CD4 cell count in subjects was observed over time in both treatment groups. Subjects who used HU experienced a slower rate of increase in absolute CD4 cell numbers, with no difference in increase in CD4 cell percentage compared with non-users. This observation is similar to reports from a previous study in which HU was shown to decrease lymphocyte counts by means of its cytostatic effect [20] .
The present study has some limitations. It had an open-label design so a reporting bias for adverse events could have been introduced. In addition, we have only limited data on adherence. Therefore, the question of whether the high failure rate observed in the as-treated population was the result of poor adherence to therapy remains unanswered.
In conclusion, our findings suggest that the addition of NVP to the triple NRTI regimen ZDV/3TC/ABC resulted in an accelerated decay in plasma viraemia and enhancement of the antiviral efficacy of the regimen. However, the higher incidence of hypersensitivity reactions in subjects who added NVP is an argument for the sequential introduction of ABC and NVP when these two agents are used in combination. The addition of HU significantly contributed to treatment failure and was poorly tolerated because of toxicity. It is regrettable that HU has proven to be that toxic, as the low cost of the drug makes it an ideal candidate for use in resource-poor settings, where effective antiretroviral therapy remains beyond the reach of most HIVinfected persons because of its cost.
